Hearing · house
“Medicines and IP: Balancing Innovation and Access”
2026-06-04 · 14:00
Source status: Scheduled
Committee
Location
2141, Rayburn House Office Building
Video
Witnesses
Ms. Krista Hessler Carver
Partner, Covington & Burling LLP
Mr. Michael Carrier
Professor, Rutgers Law School
Ms. Rachel Goode
Senior Vice President, Head of Legal and Intellectual Property
Ms. Jamie Simpson
Chief Policy Officer and Counsel, Council for Innovation Promotion
Official published hearing
Congress.gov explicitly associates this publication with this proceeding.
H.Hrg.119
MEDICINES AND IP: BALANCING INNOVATION AND ACCESS
2026-06-04 · GovInfo record 2026-08-28
Documents
Witness documents
- Witness Biography · PDF
- Witness Statement · PDF
- Witness Truth in Testimony · PDF
- Witness Biography · PDF
- Witness Statement · PDF
- Witness Truth in Testimony · PDF
- Witness Biography · PDF
- Witness Statement · PDF
- Witness Truth in Testimony · PDF
- Witness Biography · PDF
- Witness Statement · PDF
- Witness Truth in Testimony · PDF
Hearing record
- Questions for the record from Representatives Issa and Johnson for Mr. Carrier with Responses · Hearing: Questions for the Record · PDF
- Questions for the record from Representatives Issa and Johnson for Dr. Goode with Responses · Hearing: Questions for the Record · PDF
- Questions for the record from Representatives Issa and Johnson for Ms. Simpson with Responses · Hearing: Questions for the Record · PDF
- Questions for the Record from Representatives Issa, Ross, and Johnson for Ms. Carver with Responses · Hearing: Questions for the Record · PDF
Committee activity
- A statement for the record from the Biotechnology Innovation Organization, submitted for the Record by Mr. Johnson of GA · Support Document · PDF
- A letter dated June 3, 2026, from Alliance for Aging Research to Representatives Issa and Johnson regarding the ETHIC Act, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from AARP, submitted for the Record by Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the American Society of Health-System Pharmacists (ASHP), submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the Biosimilars Forum, submitted for the Record by Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the Council for Innovation Promotion, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A brief from the Center for American Principles titled, “Cap Issue Brief: Biopharmaceutical Patents”, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the Center for American Principles, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the Campaign for Sustainable Rx Pricing, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the ERISA Industry Committee (ERIC), submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from Families USA, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from Luis Abinader of Generation Patient, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from Peyton Miles of Generation Patient, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the National Association of Manufacturers, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from Patients for Affordable Drugs Now, submitted for the Record by Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the U.S. Chamber of Commerce regarding the ETHIC Act, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- An opinion from the Supreme Court of the United States in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A study from the United States Patent and Trademark Office titled, “Drug Patent and Exclusivity Study”, submitted for the Record by Mr. Kiley of CA · Support Document · PDF
- A letter dated June 2, 2026, from the Intellectual Property Owners Association to Representatives Issa and Johnson regarding the ETHIC Act, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A statement for the record from the Center for Medicine in the Public Interest, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A letter dated June 2, 2026, from the Alliance of U.S. Startups and Inventors for Jobs (USIJ) regarding the ETHIC Act, submitted for the Record by Mr. Issa of CA and Mr. Johnson of GA · Support Document · PDF
- A letter dated June 1, 2026, from the Taxpayers Protection Alliance to Representatives Issa and Johnson regarding the hearing on June 4, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A letter dated June 3, 2026, from the American Intellectual Property Law Association to Representatives Issa and Johnson, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A copy of HR 3269, the ETHIC Act, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A copy of HR 6485, the Skinny Labels, Big Savings Act, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from Blood Cancer United, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from Representative Arrington of Texas, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from NFIB, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from multiple organizations expressing support for the ETHIC Act, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A letter dated April 6, 2026, from multiple organizations to Chairman Jordan, Ranking Member Raskin, and Representatives Issa and Johnson regarding the ETHIC Act and the Skinny Labels, Big Savings Act, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from the Pharmaceutical Care Management Association, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from the Pacific Research Institute, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from We Work for Health, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from Dr. Anne Pritchett, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from Biocom, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from Public Citizen, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from the Association for Accessible Medicines and its Biosimilars Council (AAM), submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A statement for the record from the U.S. Public Interest Research Group, submitted for the Record by Mr. Issa of CA · Support Document · PDF
- A study by Rachel Goode and Bernard Chao titled, "Biological patent thickets and delayed access to biosimilars, an American problem" · Support Document · PDF
- A statement for the record from Dr. Rachel Goode regarding the ETHIC Act · Support Document · PDF
- A study titled, "Biological Patent Thickets and Terminal Disclaimers" · Support Document · PDF
- A study from the University of Pittsburgh Law Review titled, "The Long Con: An Empirical Analysis of Pharmaceutical Patent Thickets" · Support Document · PDF
Source: https://api.congress.gov/v3/committee-meeting/119/house/119346